Cigna stock rating reiterated at Overweight by Cantor Fitzgerald

Published 26/08/2025, 12:24
Cigna stock rating reiterated at Overweight by Cantor Fitzgerald

Investing.com - Cantor Fitzgerald has reiterated its Overweight rating on Cigna (NYSE:CI) with a price target of $365.00. According to InvestingPro data, analysts’ targets range from $300 to $428, with Cigna currently trading at a relatively low P/E ratio of 16.3x.

The research firm maintained its positive outlook on the health insurance company following Cigna’s exit from an Illinois county.

Cantor Fitzgerald noted that this decision aligns with Cigna’s strategic positioning statements made after the second quarter of 2025.

The firm indicated that Cigna’s county exit provides increased confidence in the company’s marketplace book for 2026.

Cantor Fitzgerald still expressed questions regarding Cigna’s reported 3% market deterioration in the second quarter of 2025, which contrasts with the 8-9% deterioration observed in data from Centene, Molina Healthcare, and Wakely.

In other recent news, Cigna Corp reported its second-quarter 2025 financial results, surpassing earnings expectations with an adjusted earnings per share of $7.20, compared to the forecast of $7.16. The company’s revenue also exceeded projections, reaching $67.2 billion against the expected $62.66 billion. Despite these positive financial results, there was a decline in Cigna’s stock, which analysts attribute to broader market concerns and specific investor reactions to the company’s operational updates and future guidance. Additionally, Guggenheim adjusted its price target for Cigna to $350 from $388, while maintaining a Buy rating on the stock. This adjustment comes after a more than 12% decline in Cigna shares since its second-quarter earnings release, compared to a decline of over 2% in the S&P 500 during the same period. Guggenheim’s decision reflects sector pressures despite Cigna’s results being in line with expectations and the company reiterating its 2025 guidance. These developments highlight the complex landscape Cigna is navigating in the current market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.